Pneumococcal vaccine conjugate 10-valent - GlaxoSmithKline
Alternative Names: 10-valent pneumococcal conjugate vaccine - GlaxoSmithKline; 10-valent pneumococcal vaccine conjugate - GlaxoSmithKline; 10Pn-PD-DiT; GSK-1024850A; PHiD-CV; Pneumococcal 10-valent vaccine conjugate - GlaxoSmithKline; Streptorix™; SynflorixLatest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; GSK
- Class Conjugate vaccines; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Otitis media; Pneumococcal infections
- Registered Pneumonia
Most Recent Events
- 08 Mar 2022 Discontinued - Phase-III for Otitis media (In children, In infants, Prevention) in Argentina (IM)
- 08 Nov 2021 Menzies School of Health Research completes a phase II/III trial in Pneumococcal infections (prevention in infants) in Vietnam (IM) (NCT01953510)
- 05 Jul 2019 Pneumococcal vaccine conjugate 10-valent is not yet available for Otitis media, Pneumococcal infections and Pneumonia in Japan